1,084 results on '"Kazuhisa Takahashi"'
Search Results
2. Endobronchial Watanabe Spigot Placement for Hepatic Abscess and Bronchobiliary Fistula Following Radiofrequency Ablation for Hepatocellular Carcinoma
3. <scp>CALML5</scp> is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type <scp>B3</scp> thymoma
4. Chemotherapy versus best supportive care in advanced lung cancer and idiopathic interstitial pneumonias: A retrospective multi-centre cohort study
5. IFN-λ3 and CCL17 as predictors of disease progression in patients with mild to moderate COVID-19: A cohort study in a real-world setting
6. Comparison of <scp>ASCL1</scp> , <scp>NEUROD1</scp> , and <scp>POU2F3</scp> expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma
7. Serum Levels of N- and C-ERC/Mesothelin and Clinicopathological Factors in Mesothelioma Patients and Those without Mesothelioma
8. Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non‐small‐cell lung cancer
9. Successful restart of chemotherapy in a patient with primary mediastinal nonseminomatous germ cell tumor after <scp>COVID</scp> ‐19 infection
10. Vogesella urethralis-induced aspiration pneumonia and bacteremia in an elderly man: a first case report and literature review
11. Study design and rationale for Marble Study: A phase II trial of atezolizumab (MPDL3280A) plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (JTD2101)
12. Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non‐small cell lung cancer patients
13. Supplementary Figure 2 from Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations
14. Supplementary Figure S5 from A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma by Suppressing LSD1
15. Supplementary Figure Legends from A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma by Suppressing LSD1
16. Supplementary Table 1 from Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations
17. Supplementary Figure 1 from Chemotherapy-Regulated microRNA-125–HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer
18. Supplementary Figure S4 from A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma by Suppressing LSD1
19. Supplementary Table 3 from Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations
20. Supplementary Figure 2 from Chemotherapy-Regulated microRNA-125–HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer
21. Data from Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations
22. Supplementary Table 2 from Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations
23. Supplementary Table S1 from A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma by Suppressing LSD1
24. Supplementary Table 6 from Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations
25. Supplementary Table 2 from Chemotherapy-Regulated microRNA-125–HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer
26. Supplementary Table 4 from Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations
27. Supplementary Figure S6 from A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma by Suppressing LSD1
28. Supplementary Figure 1 from Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations
29. Supplementary Figure S1 from A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma by Suppressing LSD1
30. Data from Chemotherapy-Regulated microRNA-125–HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer
31. Supplementary Table S2 from A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma by Suppressing LSD1
32. Supplementary Figure S3 from A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma by Suppressing LSD1
33. Data from A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma by Suppressing LSD1
34. Supplementary Figure S2 from A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma by Suppressing LSD1
35. Increased SARS-CoV-2 seroprevalence and spread of infection without awareness among healthcare workers through 2020–2022 in a Japanese medical center
36. Epidemiology, risk factors and impact of cachexia on patient outcome: Results from the Japanese Lung Cancer Registry Study
37. The synergetic effect of sitafloxacin–arbekacin combination in the Mycobacterium abscessus species
38. Pneumatosis intestinalis with free air in the abdominal cavity caused by nintedanib
39. Phase 2 Study of Osimertinib in Combination with Platinum and Pemetrexed in Patients with Previously Untreated EGFR–Mutated Advanced Non–Squamous Non–Small Cell Lung Cancer: The OPAL Study
40. Usefulness of Simultaneous Magnetic Resonance Neurography and Apparent T2 Mapping for the Diagnosis of Cervical Radiculopathy
41. Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non–Small-Cell Lung Cancer With EGFR Mutation (IMPACT)
42. Dramatic, significant metabolic response to a one‐time pembrolizumab treatment following a relapse of pre‐existing organizing pneumonia in a patient with advanced non‐small cell lung cancer: A case report
43. The Synergetic Effect of Sitafloxacin-Arbekacin Combination in the Mycobacterium abscessus Species
44. Vogesella urethralis-induced aspiration pneumonia and bacteremia in an elderly man: a first case report
45. Late relapse of ulcerative colitis presenting as tracheobronchitis: a case report
46. Thyroid storm induced by combined nivolumab and ipilimumab immunotherapy in advanced non-small cell lung cancer
47. Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study
48. A cross-population atlas of genetic associations for 220 human phenotypes
49. Highly sensitive fusion detection using plasma cell‐free RNA in non‐small‐cell lung cancers
50. Comparison of the Effectiveness of Pharmacological Treatments for Patients with Chronic Low Back Pain: A Nationwide, Multicenter Study in Japan
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.